Insmed (INSM)
Commercializes rare pulmonary disease medicines while developing pulmonary, antibody and gene therapies.
$120.82
After hours+0.03 (+0.02%)
At close$120.79(−0.17%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 100.52% | 219.52M shares | |
|---|---|---|---|
| 717 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.65% | 1.41M shares | |
| 15 holders · as of Sep 11, 2026 | |||
| Adds to | 101.17% | ||
218.38M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 101.17%; nothing is left for Other.
13F, as of Jun 30, 2026
717 holders · 219.52M shares · 115 new positions · 360 increased · 241 reduced · 123 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 16.14M | 7.39% | +2.98M | Aug 13, 2026 |
| BlackRock, Inc. | 15.81M | 7.24% | −870.2K | Aug 7, 2026 |
| JPMorgan Chase & Co | 10.43M | 4.78% | −13.72M | Aug 12, 2026 |
| Vanguard Portfolio Management LLC | 10.41M | 4.77% | +36.2K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 9.79M | 4.48% | +148.7K | Aug 13, 2026 |
| Baker Bros. Advisors LP | 8.80M | 4.03% | +1.38M | Aug 14, 2026 |
| Capital International Investors | 8.24M | 3.77% | +2.64M | Aug 12, 2026 |
| Darwin Global Management, Ltd. | 6.43M | 2.94% | −10.37M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| JPMorgan Chase & Co. | 10.80% | 23.01M | 13G | Sep 4, 2025 |
| Darwin Global Management, Ltd. | 7.80% | 16.81M | 13G | May 15, 2026 |
| BlackRock, Inc. | 6.60% | 14.12M | 13G | Jan 21, 2026 |
| FMR LLC | 6.10% | 13.15M | 13G | May 6, 2026 |
| Vanguard Capital Management | 5.34% | 11.51M | 13G | Apr 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 9, 2026 | David R. Brennandirector | Sale | 25,000 | $124.00 | 39,238 |
| Aug 17, 2026 | Melvin Md Sharokydirector | Sale | 5,000 | $127.53 | 0 |
| Aug 10, 2026 | Roger Adsettofficer: Chief Operating Officer | Sale | 239,850 | $133.27 | 98,744 |
| Aug 6, 2026 | Martina M.D. Flammerofficer: Chief Medical Officer | Sale · 2 lots | 27,173 | $128.61 | 60,486 |
| Jul 23, 2026 | William Lewisdirector, officer: Chair and CEO | Sale · 2 lots | 10,700 | $106.06 | 259,058 |
| Jul 9, 2026 | William Lewisdirector, officer: Chair and CEO | Sale · 3 lots | 10,699 | $117.40 | 259,058 |
| Jul 6, 2026 | Martina M.D. Flammerofficer: Chief Medical Officer | Sale · 2 lots | 12,302 | $109.98 | 60,486 |
| Jun 25, 2026 | William Lewisdirector, officer: Chair and CEO | Sale · 5 lots | 21,398 | $103.32 | 258,917 |
| Jun 22, 2026 | Michael Alexander Smithofficer: Chief Legal Officer | Sale | 1,806 | $95.82 | 37,648 |
| Jun 8, 2026 | William Lewisdirector, officer: Chair and CEO | Sale | 6,515 | $94.03 | 258,917 |
House and Senate disclosures
| Member | Type | Amount | Owner | Traded | Disclosed |
|---|---|---|---|---|---|
| Rep. Josh Gottheimer · NJ05 | Sale | $1,001 – $15,000 | Joint | Jun 10, 2026 | Jul 8, 2026 |